AZD3632   Click here for help

GtoPdb Ligand ID: 14672

Synonyms: example 56-1 [WO2024201240]
Compound class: Synthetic organic
Comment: AZD3632 is an orally bioavailable protein-protein interaction inhibitor that is designed to block the interaction between the tumour suppressor protein menin (MEN1, O00255) and KMT2A (MLL). It is one of the compounds claimed in patent WO2024201240A1 [1].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 85.32
Molecular weight 589.74
XLogP 3.34
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)N(C(C)C)C(=O)C1=CC(=CC=C1N2C(=C(C3=C2C=NC=C3)C(=O)C4CCN(CC4)C(=O)[C@@H]5CCC(C)(C)N5)C)F
Isomeric SMILES C1=2C(C(C3CCN(C([C@H]4NC(C)(C)CC4)=O)CC3)=O)=C(C)N(C=5C(C(N(C(C)C)C(C)C)=O)=CC(F)=CC5)C1=CN=CC2
InChI InChI=1S/C34H44FN5O3/c1-20(2)39(21(3)4)32(42)26-18-24(35)8-9-28(26)40-22(5)30(25-11-15-36-19-29(25)40)31(41)23-12-16-38(17-13-23)33(43)27-10-14-34(6,7)37-27/h8-9,11,15,18-21,23,27,37H,10,12-14,16-17H2,1-7H3/t27-/m0/s1
InChI Key SVCCZXAYHYYWPC-MHZLTWQESA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
AZD3632 has been progressed as a clinical anti-tumour agent that is proposed for advanced haematologic malignancies with MLL rearrangements
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT07155226 Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression Phase 1/Phase 2 Interventional AstraZeneca